Avacopan Shows Efficacy Signal for Rare Kidney Disease, C3G
Avacopan, recently FDA approved for ANCA-associated vasculitis, showed significant benefit for reducing disease chronicity in a randomized trial of 52 patients with C3 glomerulopathy.
Medscape Medical News
source https://www.medscape.com/viewarticle/969740?src=rss
Medscape Medical News
source https://www.medscape.com/viewarticle/969740?src=rss
Comments
Post a Comment